Angiotensin-converting enzyme inhibitors (ACEIs) have been the cornerstone in systolic heart failure (HF) regimens over the past 25 years. Their ability to block the renin–angiotensin–aldosterone system and their vasodilatory properties has repeatedly been shown to lower morbidity and mortality in patients with HF having reduced ejection fractions. In August 2014, the New England Journal of Medicine published a large trial studying a novel LCZ696 (angiotensin–neprilysin inhibition) agent against enalapril, an ACEI. In the phase III trial, LCZ696 demonstrated superiority to enalapril in composite death from cardiovascular causes and hospitalization for HF. The trial was stopped early due to overwhelming benefit of the study agent. This article provides an extensive review of the mechanism of action, pharmacokinetic properties, clinical efficacy, safety, and tolerability of LCZ696.
YancyCWJessupMBozkurtB. ACCF/AHA guideline for the management of heart failure. Circulation. 2013;128
(16):e240–e327.
2.
RizzelloVPoldermansDBiaginiE. Prognosis of patients with ischaemic cardiomyopathy after coronary revascularization: relation to viability and improvement in left ventricular ejection fraction. Heart. 2009;95
(15):1273–1277.
3.
PagleyPRBellerGAWatsonDD. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation. 1997;96
(3):793–800.
4.
FowlesREMasonJW. Endomyocardial biopsy. Ann Intern Med. 1982;97
(6):885–894.
5.
AllmanKCShawLJHachamovitchR. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39
(7):1151–1158.
6.
SchmidtDEShahPK. Accurate detection of elevated left ventricular filling pressure by a simplified bedside application of the Valsalva maneuver. Am J Cardiol. 1993;71
(5):462–465.
7.
GorodeskiEZChuECChowCH. Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. Circ Heart Fail. 2010;3
(6):706–714.
8.
CohnJNArchibaldDGZiescheS. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 1986;314
(24):1547–1552.
9.
CONSENSUS. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316
(23):1429–1435.
10.
SOLVD-Treatment. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325
(5):293–302.
11.
PittBZannadFRemmeWJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341
(10):709–717.
12.
US Carvedilol Heart Failure Study Group; PackerMBristowMRCohnJN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334
(21):1349–1355.
13.
COPERNICUS; PackerMCoatsAJSFowlerMB. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658.
14.
Val-HeFTCohnJNTognoniG. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345
(23):1667–1675.
15.
McMurrayJJVPackerMDesaiAS. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371
(11):993–1004.
McMurrayJJPackerMDesaiA. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16
(7):817–825.
18.
GuJNoeAChandraP. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50
(4):401–414.
19.
HedgeLGYuCRennerT. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol. 2011;57
(4):495–504.
20.
McDowellGCoutieWShawC. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43
(3):329–332.
21.
KostisJBPackerMBlackHR. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) Trial. Am J Hypertens. 2004;17
(2):103–111.
22.
Von LuederTGSangaralinghamSJWangBH. Renin–angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013;6
(3):594–605.
23.
PuQBrassardPJaveshghaniDM. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. J Hypertens. 2008;26
(2):322–333.
24.
McMurrayJJPackerMDesaiAS. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison and ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial. Eur J Heart Fail. 2013;15
(9):1062–1073.
25.
AyalasomayajulaSJordaanPPalP. Assessment of drug interaction potential between LCZ696 and warfarin. Hypertension. 2013;62:A448.
26.
AyalasomayajulaSJordaanPPalP. Assessment of pharmacokinetic drug interaction between LCZ696 and digoxin. Hypertension. 2013;62:A449.
27.
MendonzaAMizukiALangenickelT. Assessment of pharmacokinetic drug interaction between LCZ696 and metformin. Hypertension. 2013;62:A456.
28.
Hsui-LingHGreeleyMPalP. Assessment of pharmacokinetic drug–drug interaction between LCZ696 and carvedilol. Hypertension. 2013;62:A457.
29.
KobalavaZKotovskayaYMerayI. Clinic blood pressure in stable heart failure patients treated with the dual-acting neprilysin and angiotensin receptor inhibitor LCZ696. Eur Heart J. 2011;32
(abstract suppl.):788.
30.
KobalavaZKotovskayaYMerayI. Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP. Eur Heart J. 2011;32
(abstract suppl):784–785.
31.
JordaanP. Changes in RAAS (renin angiotensin aldosterone system) biomarkers in patients with stable chronic heart failure following short-term angiotensin receptor neprilysin inhibitor (ARNI) treatment. SA Heart. 2011;8:236.
32.
SolomonSDZileMPieskeB. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial. Lancet. 2012;380
(9851):1387–1395.
33.
McMurrayJJPackerMDesaiAS. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371
(11):993–1004.
34.
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992;327
(10):685–691.
35.
CookCColeGAsariaP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171
(3):368–376.
